• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form N-CSR/A filed by Daxor Corporation

    10/15/25 4:25:42 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    N-CSR/A 1 formncsra.htm N-CSR/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No. 1 to

    FORM N-CSR/A

     

    CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

     

    Investment Company Act file number 811-22684

     

    Daxor Corporation

    (Exact name of registrant as specified in charter)

     

    109 Meco Lane

    Oak Ridge, Tennessee 37830

    (Address of principal executive offices) (Zip code)

     

    Michael Feldschuh

    109 Meco Lane

    Oak Ridge, Tennessee 37830

    (Name and address of agent for service)

     

    212-330-8500

    Registrant’s telephone number, including area code

     

     

    Date of fiscal year end: December 31

     

    Date of reporting period: December 31, 2023

     

     

     

     
     

     

    Explanatory Note

     

    On March 15, 2024, the undersigned registrant filed its Certified Shareholder Report on Form N-CSR for the annual period ended December 31, 2023. In order to preserve flexibility with respect to potential offerings, the company engaged Bush & Associates CPA (“Bush”) to reaudit the company’s financial statements for the fiscal year ended December 31, 2023. The reaudit did not result in a restatement of, nor revisions to, the financial statements. This amendment is being made solely to file Bush’s Report of Independent Registered Public Accounting Firm regarding the fiscal year ended December 31, 2023.

     

    This amendment does not reflect events occurring after the filing of the original Certified Shareholder Report on Form N-CSR for the annual period ended December 31, 2023, and, other than attaching the Bush’s Report of Independent Registered Public Accounting Firm regarding the fiscal year ended December 31, 2023, does not modify or update the disclosures in the original Certified Shareholder Report on Form N-CSR in any way.

     

     
     

     

    ITEM 13. EXHIBITS

     

    (a) (1) Any code of ethics or amendment thereto, that is the subject of the disclosure required by Item 2, to the extent that the registrant intends to satisfy Item 2 requirements through filing an exhibit. Not Applicable.
       
      (2) Any policy required by the listing standards adopted pursuant to Rule 10D-1 under the Exchange Act by the registered national securities exchange or registered national securities association upon .which the registrant’s securities are listed.  Not Applicable.
       
      (3) A separate certification for each principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
       
      (4) Any written solicitation to purchase securities under Rule 23c-1 under the Act sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable.
       
      (5) Change in the registrant’s independent public accountant. Previously filed.
       
    (b) Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Furnished herewith.
       
    (c) Report of Independent Registered Public Accounting Firm. Filed herewith.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    (Registrant) Daxor Corporation  
         
    By (Signature and Title) /s/ Michael Feldschuh  
    Michael Feldschuh  
    President and Chief Executive Officer (Principal Executive Officer)  

     

    Date: October 15, 2025  

     

    Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this amended report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

     

    By (Signature and Title) /s/ Michael Feldschuh  
    Michael Feldschuh  
    President and Chief Executive Officer (Principal Executive Officer)  

     

    Date: October 15, 2025  

     

    By (Signature and Title) /s/ Robert J. Michel  
    Robert J. Michel  
    Chief Financial Officer and Chief Compliance Officer (Principal Financial Officer)  

     

    Date: October 15, 2025  

     

     

     

     

     

    Get the next $DXR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    4/7/25 3:23:29 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Executive Office Feldschuh Michael Richard bought $8,130 worth of Daxor Common Stock (1,000 units at $8.13), increasing direct ownership by 0.48% to 210,631 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    3/27/25 11:46:12 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Daxor with a new price target

    Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00

    3/25/21 12:00:28 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    New insider Jefferies John claimed ownership of 15,272 units of Daxor Common Stock (SEC Form 3)

    3 - DAXOR CORP (0000027367) (Issuer)

    10/2/25 3:13:38 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Desrosiers Caleb

    4 - DAXOR CORP (0000027367) (Issuer)

    6/26/25 4:24:11 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    SEC Filings

    View All

    Amendment: SEC Form N-2/A filed by Daxor Corporation

    N-2/A - DAXOR CORP (0000027367) (Filer)

    10/20/25 11:40:40 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form N-CSR/A filed by Daxor Corporation

    N-CSR/A - DAXOR CORP (0000027367) (Filer)

    10/15/25 4:25:42 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form N-PX filed by Daxor Corporation

    N-PX - DAXOR CORP (0000027367) (Filer)

    9/2/25 5:27:36 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

    Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City. Mr. Feldschuh will be available for one-on-one meetings with institutional investors and will also meet with senior Maxim analysts throughout the event. The conference features high-profile

    10/21/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor's New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

    OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across the country. "We are thrilled to debut our eagerly awaited next generation BVA diagnostic system at this pivotal gathering," said Michael Feldschuh, Daxor's CEO and President. "This launch

    10/15/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

    Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company's successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market. The initial response from clinicians confirmed robust market demand for the new system, driven b

    9/30/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Leadership Updates

    Live Leadership Updates

    View All

    Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

    Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe

    6/5/24 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Appoints Linda Cooper, Vice President Project Management

    Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh

    2/17/23 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Financials

    Live finance-specific insights

    View All

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

    Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important

    9/2/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

    Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

    3/4/25 4:55:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

    Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

    3/4/25 3:53:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care